Delisted from Euronext Paris in Aug 2024
MRK - Merck & Co., Inc.
PAR
->
Healthcare
->
Drug Manufacturers—General
Kenilworth,
United States
Type: Equity
MRK price evolution
MRK
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $12174 | $12406 | $12110 | $11072 |
| Inventory | $6244 | $6469 | $6510 | $6358 |
| Total current assets | $40361 | $38205 | $31445 | $32168 |
| Long term investments | ||||
| Property, plant & equipment | $23446 | $23221 | $23045 | $23051 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $117532 | $112630 | $105849 | $106675 |
| Current liabilities | ||||
| Accounts payable | $3586 | $3519 | $3514 | $3922 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $29586 | $26060 | $25099 | $25694 |
| Long term debt | $34982 | $34717 | $31142 | $33683 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $73030 | $69048 | $65485 | $69094 |
| Shareholders' equity | ||||
| Retained earnings | $61384 | $60187 | $56697 | $53895 |
| Other shareholder equity | -$5371 | -$5361 | -$5274 | -$5161 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8062 | |||
| Short term investments | ||||
| Net receivables | $11072 | $9450 | $9230 | $7851 |
| Inventory | $6358 | $5911 | $5953 | $6310 |
| Total current assets | $32168 | $35722 | $30266 | $27764 |
| Long term investments | ||||
| Property, plant & equipment | $24488 | $22768 | $19279 | $17986 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63824 | |||
| Total investments | ||||
| Total assets | $106675 | $109160 | $105694 | $91588 |
| Current liabilities | ||||
| Accounts payable | $3922 | $4264 | $4609 | $4594 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $25694 | $24239 | $23872 | $27327 |
| Long term debt | $33683 | $28745 | $30690 | $25360 |
| Total noncurrent liabilities | $38857 | |||
| Total debt | ||||
| Total liabilities | $69094 | $63169 | $67510 | $66184 |
| Shareholders' equity | ||||
| Retained earnings | $53895 | $61081 | $53696 | $47362 |
| Other shareholder equity | -$5161 | -$4768 | -$4429 | -$6547 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $16657 | $16112 | $15775 | |
| Cost of revenue | ||||
| Gross Profit | $13408 | $13039 | $12814 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $8495 | $6164 | $6431 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $929 | $545 | $903 | |
| Interest expense | -$58 | $49 | $116 | |
| Net income | ||||
| Net income | $3157 | $5455 | $4762 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $60115 | $59283 | $48704 | $47994 |
| Cost of revenue | ||||
| Gross Profit | $46218 | $44136 | $35463 | $32509 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $40007 | $21614 | $19896 | $24026 |
| Operating income | $8483 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $1512 | $1918 | $1521 | $1709 |
| Interest expense | $279 | -$1348 | $873 | |
| Net income | ||||
| Net income | $365 | $14519 | $13049 | $7067 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$6290 | -$2445 | -$1376 | -$14083 |
| Financing activities | ||||
| Dividends paid | -$5889 | -$3936 | -$1950 | -$7445 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$4023 | -$1598 | -$2814 | -$4810 |
| Effect of exchange rate | $74 | -$220 | -$138 | $23 |
| Change in cash and equivalents | $7779 | $4464 | -$1238 | -$5864 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | $7082 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $10253 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$14083 | -$4960 | -$16555 | -$9443 |
| Financing activities | ||||
| Dividends paid | -$7445 | -$7012 | -$6610 | -$6215 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$4810 | -$9119 | $2593 | -$2832 |
| Effect of exchange rate | $23 | -$410 | -$133 | $253 |
| Change in cash and equivalents | -$5864 | $4606 | $14 | -$1769 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 2.53B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 4.35% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.36 |
| Quick ratio | 1.15 |